[go: up one dir, main page]

WO1998017284A3 - Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy - Google Patents

Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy Download PDF

Info

Publication number
WO1998017284A3
WO1998017284A3 PCT/CA1997/000794 CA9700794W WO9817284A3 WO 1998017284 A3 WO1998017284 A3 WO 1998017284A3 CA 9700794 W CA9700794 W CA 9700794W WO 9817284 A3 WO9817284 A3 WO 9817284A3
Authority
WO
WIPO (PCT)
Prior art keywords
heparin
hiv
mimetics
cap
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1997/000794
Other languages
French (fr)
Other versions
WO1998017284A2 (en
Inventor
Daniel Favre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU47691/97A priority Critical patent/AU4769197A/en
Publication of WO1998017284A2 publication Critical patent/WO1998017284A2/en
Publication of WO1998017284A3 publication Critical patent/WO1998017284A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method of inhibiting cap-independent protein synthesis of eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to said eukaryotic cells. There is also disclosed a method of inhibiting translation of HIV TAR-containing messenger ribonucleic acids (mRNA) of HIV infected eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to said eukaryotic cells. There is also disclosed a composition for gene therapy using glycosaminoglycan N-acetylglycosaminyl N-deacetylase/N-sulfotransferase cDNA.
PCT/CA1997/000794 1996-10-22 1997-10-21 Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy Ceased WO1998017284A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU47691/97A AU4769197A (en) 1996-10-22 1997-10-21 Inhibition of cap-independent protein synthesis by heparin or heparin mimetics thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2873696P 1996-10-22 1996-10-22
US60/028,736 1996-10-22
US3201896P 1996-11-22 1996-11-22
US60/032,018 1996-11-22

Publications (2)

Publication Number Publication Date
WO1998017284A2 WO1998017284A2 (en) 1998-04-30
WO1998017284A3 true WO1998017284A3 (en) 1998-08-20

Family

ID=26704031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000794 Ceased WO1998017284A2 (en) 1996-10-22 1997-10-21 Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy

Country Status (2)

Country Link
AU (1) AU4769197A (en)
WO (1) WO1998017284A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353556A4 (en) 2001-01-23 2009-09-09 Massachusetts Inst Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907303A1 (en) * 1978-02-24 1979-09-06 Demetrios P Papahadjopoulos PROCESS FOR ENCAPSULATING BIOLOGICALLY ACTIVE SUBSTANCES
JPS59222410A (en) * 1983-06-01 1984-12-14 Terumo Corp Pharmaceutical preparation of liposome for keeping drug
WO1992013524A1 (en) * 1991-02-07 1992-08-20 A. Nattermann & Cie. Gmbh Pharmaceutical for treating viral diseases
JPH07145038A (en) * 1993-11-26 1995-06-06 Terumo Corp Constituent component for membrane of small closed cell
JPH0827030A (en) * 1994-07-08 1996-01-30 Terumo Corp Medicine carrier recognizing kidney

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907303A1 (en) * 1978-02-24 1979-09-06 Demetrios P Papahadjopoulos PROCESS FOR ENCAPSULATING BIOLOGICALLY ACTIVE SUBSTANCES
JPS59222410A (en) * 1983-06-01 1984-12-14 Terumo Corp Pharmaceutical preparation of liposome for keeping drug
WO1992013524A1 (en) * 1991-02-07 1992-08-20 A. Nattermann & Cie. Gmbh Pharmaceutical for treating viral diseases
JPH07145038A (en) * 1993-11-26 1995-06-06 Terumo Corp Constituent component for membrane of small closed cell
JPH0827030A (en) * 1994-07-08 1996-01-30 Terumo Corp Medicine carrier recognizing kidney

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHANNAVAJJALA ET AL.: "CELL SURFACE HEPARIN PROTEOGLYCAN MEDIATE ATTACHMENT TO BASIC DOMAIN OF HIV-1 TAT PROTEIN", AIDS RES. HUMAN RETROV., vol. 10, no. suppl. 3, 1994, pages s77, XP002056009 *
DATABASE WPI Section Ch Week 8505, Derwent World Patents Index; Class B05, AN 85-027827, XP002056019 *
DATABASE WPI Section Ch Week 9531, Derwent World Patents Index; Class B04, AN 95-237131, XP002056018 *
DATABASE WPI Section Ch Week 9614, Derwent World Patents Index; Class A96, AN 96-136210, XP002056017 *
GREENBERG ET AL.: "Effect of Protein Synthesis Inhibitors on Growth Factor Activation of c-fos, c-myc, and Actin Gene Transcription", MOL. CELL. BIOL., vol. 6, no. 4, 1986, pages 1050 - 1057, XP002056016 *
HALPER ET AL.: "Modulation of Growth of Human Carcinoma SW-13 Cells by Heparin and Growth Factors", J. CELL. PHYS., vol. 141, no. 1, 1989, pages 16 - 23, XP002056011 *
HOWELL ET AL.: "LOW MOLECULAR WEIGHT HEPARIN INHIBITS INFECTIVITY AND PREVENTS REPLICATION OF HIV-1 IN T CELLS", BLOOD, vol. 84, no. 10 suppl. 1, 1994, pages 701a, XP002056015 *
MANALAYSAY ET AL.: "Inhibition of Mesothelial Cell Growth and Protein Synthesis by Heparin", ADV. PERITON. DIAL., vol. 11, 1995, pages 239 - 242, XP002056007 *
MEYLAN ET AL.: "Influence of Host Cell Type and V3 Loop of the Surface Glycoprotein on Susceptibility of Human Immunodeficiency Virus Type 1 to Polyanion Compounds", ANTIMICROBIAL AGENTS CHEMOTHER., vol. 38, no. 12, 1994, pages 2910 - 2916, XP002056014 *
REILLY ET AL.: "Rat Vascular Smooth Muscle Cells Immortalized with SV40 Large T antigen Possess Defined Smooth Muscle Inhibition by Heparin", J. CELL. PHYS., vol. 142, no. 2, 1990, pages 342 - 351, XP002056012 *
WACKER ET AL.: "Spezifische und unspezifische Hemmung der zellfreien Proteinsynthese mit Polyanionen", Z. NATURFORSCH. B, vol. 22, no. 4, 1967, pages 413 - 417, XP002056008 *
WALDMAN ET AL.: "Heparin as inhibitor of mammalian protein synthesis. II. Degree of sulfation. Related sulfated mucopolysaccharides", BIOCHIM. BIOPHYS. ACTA, vol. 343, no. 2, 1974, pages 324 - 329, XP002056010 *
WITVROUW ET AL.: "Sulfated polysaccharides Extracted from Sea Algae as Potential Antiviral Drugs", GEN. PHARMAC., vol. 29, no. 4, 1997, pages 497 - 511, XP002056013 *

Also Published As

Publication number Publication date
WO1998017284A2 (en) 1998-04-30
AU4769197A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
AU5610398A (en) Method of treating or preventing septic shock by administering a mek inhibitor
AU3367995A (en) New multimerizing agents
AU7714594A (en) Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
WO2000071703A3 (en) Inhibition of histone deacetylase
WO1999054326A8 (en) Dihydropyrimidines
AU6583696A (en) Methods for reducing inhibition of nucleic acid amplification
WO1999020799A3 (en) Microorganism genomics, compositions and methods related thereto
WO1999046372A3 (en) Ribozymes capable of inhibiting the expression of the ccr5 receptor
AU3631197A (en) N-benzylpiperidine and tetrahydropyridine derivatives
AU5299696A (en) Methods of inhibiting cell-cell adhesion
AU2590895A (en) Derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA)
AUPN816196A0 (en) Regulation of eukaryotic gene expression
WO1999051727A3 (en) Human nucleic acid sequences of normal ovary tissue
AU5652698A (en) (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
WO1997027276A3 (en) Nucleic acids encoding polypeptides having absidia lipase activity
EP1681350A3 (en) Porphorymonas gingivalis polypeptides and polynucleotides
AU1605699A (en) Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (ii)
WO1997046569A3 (en) 2'-substituted nucleosides and oligonucleotide derivatives
WO1998017284A3 (en) Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy
EP0983243A4 (en) Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
AU4515699A (en) Tagging of rna amplicons generated by transcription-based amplification
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
AU8297698A (en) Inhibitors of neutrophil mediated oxidant production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA